December 20, 2014 8:55 AM ET

Healthcare Equipment and Supplies

Company Overview of Tethys Bioscience, Inc.

Company Overview

Tethys Bioscience, Inc., a cardiometabolic diagnostics company, develops and commercializes biomarker-based blood tests that predict imminent disease risk and enable targeted intervention to preempt the onset of chronic conditions. Its portfolio includes PreDx Diabetes Risk Score, a blood test that combines multiple blood-borne markers and an algorithm to deliver the risk stratification for patients at risk for type 2 diabetes; Reduce My Risk Diabetes Prevention Initiative, an educational program targeted to individuals who are at high risk for type 2 diabetes but have not yet developed the disease; and PreDx test, a multi-biomarker blood test used for the stratification and monitoring of pr...

5858 Horton Street

Suite 280

Emeryville, CA 94608

United States

Founded in 2005





Key Executives for Tethys Bioscience, Inc.

Chief Executive Officer and President
Age: 59
Age: 62
Chief Medical Officer
Vice President of Sales
Age: 52
Senior Vice President of Marketing
Compensation as of Fiscal Year 2014.

Tethys Bioscience, Inc. Key Developments

Tethys Bioscience Is Reportedly Up For Sale

Tethys Bioscience, Inc. is up for sale. Tethys BioScience is shutting down after failing to win approval for Medicaid reimbursements for its diabetes tests, Fortune's Dan Primack reported. He added that company investors are now looking for buyers for the company's assets.

Tethys Bioscience, Inc. Announces PreDx Test Now Available With Finger Stick Collection Method

Tethys Bioscience has announced that the PreDx test, a multi-biomarker blood test used for the stratification and monitoring of prediabetes patients, can now be performed using capillary blood collected via a simple finger stick procedure. The PreDx test measures seven biomarkers implicated in the development of type 2 diabetes, and utilizes a proprietary algorithm to generate a 'personalized' numerical score that ranks a prediabetic's 5-year risk of progression to diabetes on a scale of 1 to 10, with a higher score indicating a higher 5-year risk of progression. Baseline scores are used to stratify prediabetes patients into low, moderate or high- risk categories for disease progression, then retesting is used to monitor changes in the patient's score, which reflect the efficacy of preventive interventions in reducing the patient's level of risk.

Tethys Bioscience, Inc. Presents at 25th Annual ROTH Conference, Mar-20-2013 10:30 AM

Tethys Bioscience, Inc. Presents at 25th Annual ROTH Conference, Mar-20-2013 10:30 AM. Venue: The Ritz-Carlton, 1 Ritz Carlton Drive, Dana Point, Laguna Niguel, California, United States.

Similar Private Companies By Industry

Company Name Region
PAXmed Inc. United States
Barnev Inc. United States
New World Medical, Inc. United States
Remicalm, LLC United States
OX-GEN Flexible Life Systems, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tethys Bioscience, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at